Skip to main content
NurExone Biologic Inc logo

NurExone Biologic Inc — Investor Relations & Filings

Ticker · NRX ISIN · CA67059R1091 LEI · 25490047UWNZ2P8ESB77 TSXV Manufacturing
Open in API
Filings indexed 241 across all filing types
Latest filing 2026-04-16 Audit Report / Informat…
Country CA Canada
Listing TSXV NRX

About NurExone Biologic Inc

https://nurexone.com/

NurExone Biologic Inc. is a biopharmaceutical technology company specializing in the development of regenerative exosome-based therapies for Central Nervous System (CNS) injuries. The core of its business is the proprietary ExoTherapy platform, which utilizes nanosized extracellular vesicles (exosomes) as precision biological messengers and drug delivery vehicles. These exosomes are loaded with therapeutic compounds, creating nanodrugs designed to target inflamed or damaged neural tissue. A key product candidate is ExoPTEN, an siRNA sequence loaded onto exosomes, which has shown promise in regenerating and rewiring neurons in preclinical models of fully transected spinal cords. The company employs proprietary 2D and 3D production processes within its dedicated in-house bioreactor to ensure high-quality, large-scale production of potent exosomes.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 95% confidence The document is the audited consolidated financial statements of NurExone Biologic Inc. for the year ended December 31, 2025, including the independent auditor’s report, notes, and full financial statements. It does not include broader narrative sections typical of a full Annual Report (10-K) or MD&A beyond a reference, and is clearly a standalone audit report with financial statements. Therefore, it fits the definition of a standalone Audit Report / Information (AR). FY 2025
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 62% confidence The document is a press‐style announcement of a non‐binding Letter of Intent (LOI) between NurExone’s subsidiary and BioXtek for a strategic partnership in exosome manufacturing. It does not present financial results (ER, IR, 10-K), management discussion (MDA), or board changes (MANG), nor is it a formal M&A bid (TAR) or dividend/share issuance (DIV, SHA). It reads as a general corporate announcement without fitting a more specific category, so it defaults to the Regulatory Filings fallback category (RNS).
2026-04-07 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the publication of a peer‐reviewed preclinical study, not a financial report, regulatory form, dividend notice, or management change. It does not contain financial statements or voting results, nor is it a formal company report like an annual or interim report; rather, it is a general company news announcement. It does not fit any specific category such as earnings release, capital update, or M&A. Therefore, it falls into the fallback “Regulatory Filings” category for miscellaneous corporate announcements (RNS).
2026-04-07 English
News release - English.pdf
Regulatory Filings Classification · 35% confidence The document is a corporate press release announcing a non-binding letter of intent for a strategic exosome manufacturing partnership. It does not present quarterly or annual financial results (so not 10-K, IR, ER, MDA), nor is it a fundraising/capital-markets update (CAP), M&A takeover or share issue (TAR/SHA), governance or AGM material (AGM-R/CGR/PSI), insider dealings (DIRS), dividends (DIV), or legal/litigation disclosure (LTR). It is a general business announcement that does not fit any specific category, making "Regulatory Filings" (RNS) the appropriate fallback.
2026-04-07 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing a non-binding Letter of Intent (LOI) between NurExone Biologic's U.S. subsidiary and BioXtek for a strategic partnership in exosome manufacturing and commercialization. It discusses the intended collaboration, potential future agreements, and forward-looking statements. There are no financial statements, regulatory filings, voting results, or management changes reported. The document is a corporate announcement about a strategic business development rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The best fitting category is Capital/Financing Update (CAP) because it relates to a strategic partnership and potential future commercial and manufacturing activities that could impact the company's capital and business operations.
2026-04-07 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing NurExone’s award and engagement of a marketing/IR firm. It contains no financial results (earnings) nor management discussion, no regulatory report attached, no share transactions, or other specific event categories. It is a general business update, so it falls into the fallback “Regulatory Filings” category (RNS).
2026-04-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.